Dr Link is a CSIC researcher at Institute of Biomedical Research Alberto Sols (Madrid) focused on drug resistance mechanisms in cancer. He is also group leader at the Algarve Biomedical Center Research Institute (ABC-RI), and holds a position as an invited assistant professor at the Faculdade de Medicina e Ciências Biomédicas (FMBC) at the Universidade do Algarve (UAlg) in Faro and professor honorário at the Universidad Autónoma, Madrid (UAM). He is co-founder of Refoxy Pharma GMBH, Berlin/Boston, a biotech company dedicated to target FOXO proteins (www.refoxy.com). Dr Link counts with more than 25 years of experience in basic and translational biomedical research. He holds three patents (one licensed to Sanofi), published three books, three book chapters and over 90 articles (4 more under revision), 11 as first author, over 40 as senior author. He published articles (selection) in Nature, Oncogene, PNAS, Nature Reviews Drug Discovery, Trends in Biotechnology, EMBO J, The Lancet Oncology, Trends in Pharmacological Sciences, Drug Resistance Updates and Aging Cell. His work has been cited 6478 times. He also serves as an editorial board member of prestigious, international peer reviewed journals including Cancers, Frontiers in Oncology and Frontiers in Cell and Developmental Biology. Dr Link built an extensive network of contacts and collaborations (member of three COST actions, majority of published papers from the Link lab include national and international collaborators). He has a proven track-record in drug discovery and drug development and has recently published a textbook on that topic (Link W. Springer Nature 2019). Dr Link acts as an expert evaluator for funding organisations including ERC (EU), The Brain Tumour Charity (UK), Leuka (UK), Dutch Cancer Society (Netherlands), Austrian Science Fund (ASF, Austria), ANEP (Spain), FCT (Portugal), MOH, AIFA (Italy), University of Macau (China), HRC (New Zealand). He also serves as a peer-reviewer for (selection) Carcinogenesis, Chemical Reviews, Drug Discovery Today, FEBS Letters, Hepatology, International Journal of Cancer, J Cell Science, Nature Chemical Biology, Nature Comm., Oncogene, PloS ONE, PNAS, Scientific Reports, Trends in Cell Biology. Importantly, the Link group was one of the first to identify CRM1 inhibitors and ever since was on the forefront of CRM1 drug discovery. He identified TRIB2 as an oncogene involved in therapy resistance. Dr Link obtained his PhD degree from the University of Hamburg, followed by a postdoc at CNB, Madrid before joining the pharma company EleGene AG (Germany) as a senior scientist. In 2001, he moved to Madrid joining the newly-founded CNIO where he was promoted to head the screening group in 2010. In 2012, he accepted a position as an assistant professor at the UAlg, Faro, Portugal where he was head of the Department of Oncobiology and director of the Masters program on Molecular mechanisms of cancer. In 2018, he also joined the Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM) in Madrid, Spain as a CSIC researcher and group leader. Five greatest contributions to science: 1. Cloning of Arg3.1/ARC, one of the most important genes in neuroscience and synaptic plasticity (Proc. Natl. Acad. Sci. USA 92, 5734-5738. doi: 10.1073/pnas.92.12.5734) 2. Cloning of DREAM, the first transcription factor directly regulated by calcium (Nature, 398, 80-84. doi: 10.1038/18044) 3. Identifying genetic and pharmacological means to activate FOXO transcription factors considered as key tumor suppressors and longevity genes (Nature Reviews Drug Discovery 20, 21-38. doi: 10.1038/s41573-020-0088-2) 4. Characterizing TRIB2 as an oncogene in Melanoma that confers therapy resistance (Nature Comm. 8, 14687. doi: 10.1038/ncomms14687) 5. Generating high content screening (HCS) technology to identify CRM1 inhibitors (Trends Biotechnol. 28, 237-245. (Title story + Cover art) doi: 10.1016/j.tibtech.2010.02.005)

Personal identification

Full name
Wolfgang Link

Citation names

  • Link, Wolfgang

Author identifiers

Ciência ID
Google Scholar ID
Researcher Id
Scopus Author Id


Knowledge fields

  • Medical and Health Sciences - Medical Biotechnology
  • Natural sciences - Biological Sciences - Cell Biology
  • Natural sciences - Biological Sciences - Biology
  • Natural sciences - Biological Sciences - Molecular Biology
  • Medical and Health Sciences - Clinical Medicine - Oncology


Language Speaking Reading Writing Listening Peer-review
German (Mother tongue)
English Proficiency (C2) Proficiency (C2) Proficiency (C2) Proficiency (C2) Proficiency (C2)
Spanish; Castilian Proficiency (C2) Proficiency (C2) Proficiency (C2) Proficiency (C2) Proficiency (C2)
Portuguese Upper intermediate (B2) Upper intermediate (B2) Intermediate (B1) Intermediate (B1) Intermediate (B1)
Degree Classification
2000/03/15 - 2001/01/31
Centro Nacional de Biotechnologia (CNB) (Postgraduate Certificate)
Consejo Superior de Investigaciones Científicas, Spain
1995/04/01 - 2000/03/14
Universität Hamburg (Doktor (PhD))
Universität Hamburg, Germany
"Molekulare und funktionelle Charakterisierung des transkriptionellen repressors DREAM" (THESIS/DISSERTATION)
1994/04/01 - 1995/03/31
Diploma thesis (Master)
Universitätsklinikum Hamburg-Eppendorf Zentrum für Molekulare Neurobiologie Hamburg, Germany
"Die somatodentritische Expression eines bisher unbekannten, unmittelbar frühen gens wird durch synaptische Aktivität reguliert" (THESIS/DISSERTATION)
1987/04/01 - 1994/03/31
Study of Biology (Licence)
Universität Hamburg Department Biologie, Germany


Host institution
2011/12/01 - Current Principal Investigator (Research) Universidade do Algarve - Campus de Gambelas, Portugal
Universidade do Algarve Centro de Investigação em Biomedicina, Portugal
2010/11/01 - 2011/11/30 Principal Investigator (Research) Centro Nacional de Investigaciones Oncológicas, Spain
2001/09/01 - 2010/10/31 Researcher (Research) Centro Nacional de Investigaciones Oncológicas, Spain
2000/10/01 - 2001/08/31 Principal Investigator (Research) Elegene GMBH, Germany

Teaching in Higher Education

Host institution
2021/01/01 - Current Tutor (University Teacher) Fundación de la Universidad Autónoma de Madrid, Spain
Fundación de la Universidad Autónoma de Madrid, Spain
2018/07/31 - Current Invited Assistant Professor (University Teacher) Universidade do Algarve - Campus de Gambelas, Portugal
2013 - 2018 Assistant Professor (University Teacher) Universidade do Algarve, Portugal

Positions / Appointments

Host institution
2013 - 2018 Conselho científico/técnico-científico ou orgão correspondente Universidade do Algarve, Portugal


Host institution
2020/12/01 - Current Biotech Company Rexoxy Pharmaceuticals, GMBH, Germany


Designation Funders
2019/09 - 2021/09 Targeting TRIB2-mediated drug resistance in melanoma (RESIST)
Gobierno de España Ministerio de Ciencia Innovación y Universidades
2019/09 - 2020/08 Superar la resistencia a medicamentos en glioma
Gobierno de España Ministerio de Ciencia Innovación y Universidades
2019/04/01 - 2020/03/31 Using natural products from regional grapes/wine capable of regulating FOXO factors as potential anti-aging drugs
CBMR Synergy Grant 2019
Principal investigator
2017/09/01 - 2020/03/31 RED transfronteriza para el desarrollo de productos innovadores con microALGAs
Principal investigator
2019/04 - 2020/03 Using natural products from regional grapes/wine capable of regulating FOXO factors as potential anti-aging drugs
CBMR Synergy Grant 2019
2018/12/01 - 2019/11/30 Characterization of therapy-induced stabilization of the drug resistance protein TRIB2
Intermural CSIC grannt
Principal investigator
Consejo Superior de Investigaciones Científicas, Spain
2017/02/01 - 2018/01/31 Characterizing the clinical relevance and the mechanism underlying TRIB2-mediated drug resistance to MEK inhibitiors in the context of melanoma
LPCC-NRS/Terry Fox 2017-2018
Principal investigator
Liga Portuguesa Contra o Cancro
2015/06/01 - 2016/05/31 Role of TRIB2 in the progression of Breast Cancer
Bolsa Laço 2015
Principal investigator
Universidade do Algarve - Campus de Gambelas, Portugal
2014/03/01 - 2015/02/28 Impact of FOXO activators on aging
NIH U19 AG023122
Principal investigator
National Institutes of Health
2014/03 - 2015/02 Impact of FOXO activators on aging
NIH U19 AG023122
National Institutes of Health
2013/04 - 2014/03 The role of tribbles homolog 2 (TRIB2) in drug resistance (e.g. to BAY 80-6946, and BAY 1082439, BAY 1001931 and BAY 86-9766) andits potential use as a biomarker to predict resistance to PI3K/Akt and MEK inhibitors
Grant4Target 2013
Bayer Corp
2006/09/01 - 2009/08/31 Identificación de compuestos líder y dianas terapéuticas: Utilización de la vía de PI3K/Akt para el descubrimiento de compuestos anticancerígenos
Principal investigator
Gobierno de España
2002/03/01 - 2005/02/28 Desarrollo de ensayos celulares basados en la vía PI3’K/Akt para el descubrimiento de moléculas líder con potencial antitumoral
Principal investigator
Gobierno de España


Designation Funders
2020/12/01 - Current Developing small molecule FOXO activator compounds to treat age-related diseases and promote healthy aging
R&D Apollo
2017/09/01 - 2020/08/31 TRIBBLES
Universidade do Algarve - Campus de Gambelas, Portugal
EU Framework Programme for Research and Innovation Marie Sklodowska-Curie Actions


  1. Link, W.. Introduction to FOXO biology. 2019.
  2. Barradas, M.; Link, W.; Megias, D.; Fernandez-Marcos, P.J.. High-throughput image-based screening to identify chemical compounds capable of activating FOXO. 2019.
  3. Machado, S.; Raposo, C.; Ferreira, B.I.; Link, W.. Image-based identification of chemical compounds capable of trapping FOXO in the cell nucleus. 2019.
  4. Link, W.. Preface. 2019.
  5. Wolfgang Link. FOXO Transcription Factors. Springer New York. 2019.
  6. Henriques, V.; Machado, S.; Link, W.; Ferreira, B.I.. Monitoring the transcriptional activity of FOXO transcription factors by analyzing their target genes. 2019.
  7. Link, Wolfgang. Principles of Cancer Treatment and Anticancer Drug Development. 2019.
  8. Cautain, B.; de Pedro, N.; Reyes, F.; Link, W.. Image-based identification of nuclear export inhibitors from natural products. 2015.
  9. Link, Wolfgang. International Manual of Oncology Practice. 2015.
  10. Evensen, L.; Link, W.; Lorens, J.B.. Image-based high-throughput screening for inhibitors of angiogenesis. 2012.
Dictionary entry
  1. Florindo, Claudia; Ferreira, Bibiana I; Serrão, Sónia M; Tavares, Álvaro A; Link, Wolfgang. "Subcellular Protein Localisation in Health and Disease". In eLS. John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9780470015902.a0026534.
Journal article
  1. De Sousa-Coelho, Ana Luísa; Gacias, Mar; O'Neill, Brian T.; Relat, Joana; Link, Wolfgang; Haro, Diego; Marrero, Pedro F.. "FOXO1 represses PPARa-Mediated induction of FGF21 gene expression". Biochemical and Biophysical Research Communications 644 (2023): 122-129. http://dx.doi.org/10.1016/j.bbrc.2023.01.012.
  2. Orea-Soufi, Alba; Paik, Jihye; Bragança, José; Donlon, Timothy A.; Willcox, Bradley J.; Link, Wolfgang. "FOXO transcription factors as therapeutic targets in human diseases". Trends in Pharmacological Sciences 43 12 (2022): 1070-1084. http://dx.doi.org/10.1016/j.tips.2022.09.010.
  3. Jimenez, Lucia; Mayoral-Varo, Victor; Amenábar, Carlos; Ortega, Judit; Sequeira, João G. N.; Machuqueiro, Miguel; Mourato, Cristiana; et al. "Multiplexed cellular profiling identifies an organoselenium compound as an inhibitor of CRM1 -mediated nuclear export". Traffic 23 12 (2022): 587-599. http://dx.doi.org/10.1111/tra.12872.
  4. De Sousa-Coelho, Ana Luísa; Aureliano, Manuel; Fraqueza, Gil; Serrão, Gisela; Gonçalves, João; Sánchez-Lombardo, Irma; Link, Wolfgang; Ferreira, Bibiana I.. "Decavanadate and metformin-decavanadate effects in human melanoma cells". Journal of Inorganic Biochemistry 235 (2022): 111915. http://dx.doi.org/10.1016/j.jinorgbio.2022.111915.
  5. Lucia Jimenez; Carlos Amenabar; Victor; Thomas A. Mackenzie; Carmen Ramos; Andreia Silva; Giampaolo Calissi; et al. "mTORC2 Is the Major Second Layer Kinase Negatively Regulating FOXO3 Activity". Molecules (2022): https://www.mdpi.com/1420-3049/27/17/5414.
  6. Passirani, Catherine; Vessières, Anne; La Regina, Giuseppe; Link, Wolfgang; Silvestri, Romano. "Modulating undruggable targets to overcome cancer therapy resistance". Drug Resistance Updates 60 (2022): 100788. http://dx.doi.org/10.1016/j.drup.2021.100788.
  7. Faleiro, Inês; Roberto, Vânia Palma; Demirkol Canli, Secil; Fraunhoffer, Nicolas A.; Iovanna, Juan; Gure, Ali Osmay; Link, Wolfgang; Castelo-Branco, Pedro. "DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study". Cancers 13 24 (2021): 6354. http://dx.doi.org/10.3390/cancers13246354.
  8. Mónica T. Fernandes; Victor Yassuda; José Bragança; Wolfgang Link; Bibiana I. Ferreira; Ana Luísa De Sousa-Coelho. "Tribbles Gene Expression Profiles in Colorectal Cancer". Gastrointestinal Disorders 3 4 (2021): 218-236. https://doi.org/10.3390/gidisord3040021.
  9. Jimenez, Lucia; Silva, Andreia; Calissi, Giampaolo; Grenho, Inês; Monteiro, Rita; Mayoral-Varo, Victor; Blanco-Aparicio, Carmen; et al. "Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3". The Journals of Gerontology: Series A (2021): http://dx.doi.org/10.1093/gerona/glab265.
    Published • 10.1093/gerona/glab265
  10. Link, Wolfgang; Ilardi, Gennaro; Zannetti, Antonella. "Editorial: Tumor Microenvironment: Molecular Mechanisms and Signaling Pathways Involved in Metastatic Progression". Frontiers in Oncology 11 (2021): http://dx.doi.org/10.3389/fonc.2021.730815.
    Published • 10.3389/fonc.2021.730815
  11. Bibiana I. Ferreira; Bruno Santos; Wolfgang Link; Ana Luísa De Sousa-Coelho. "Tribbles Pseudokinases in Colorectal Cancer". Cancers 13 11 (2021): 2825-2825. https://doi.org/10.3390/cancers13112825.
  12. Victor Mayoral-Varo; Lucía Jiménez; Wolfgang Link. "The Critical Role of TRIB2 in Cancer and Therapy Resistance". Cancers (2021): https://doi.org/10.3390/cancers13112701.
  13. Pérez-Beltrán, Christian Hazael; García-Guzmán, Juan José; Ferreira, Bibiana; Estévez-Hernández, Osvaldo; López-Iglesias, David; Cubillana-Aguilera, Laura; Link, Wolfgang; et al. "One-minute and green synthesis of magnetic iron oxide nanoparticles assisted by design of experiments and high energy ultrasound: Application to biosensing and immunoprecipitation". Materials Science and Engineering: C (2021): 112023. http://dx.doi.org/10.1016/j.msec.2021.112023.
    Open access • 10.1016/j.msec.2021.112023
  14. Giampaolo Calissi; Eric W.-F. Lam; Wolfgang Link. "Therapeutic strategies targeting FOXO transcription factors". Nature Reviews Drug Discovery (2021): https://doi.org/10.1038/s41573-020-0088-2.
  15. Machado S; Andreia Silva; Ana Luísa De Sousa-Coelho; Isabel Duarte; Inês Grenho; Bruno Santos; Victor Mayoral-Varo; et al. "Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance". Cancers (2020): https://www.mdpi.com/2072-6694/12/12/3689.
  16. Ferreira, Bibiana I.; Cautain, Bastien; Grenho, Inês; Link, Wolfgang. "Small Molecule Inhibitors of CRM1". Frontiers in Pharmacology 11 (2020): http://dx.doi.org/10.3389/fphar.2020.00625.
  17. Link, Wolfgang. "CRISPR/Cas9-mediated genome editing: From basic research to translational medicine". Journal of Cellular and Molecular Medicine (2020): http://dx.doi.org/10.1111/jcmm.14916.
  18. Cui, Bing; Eyers, Patrick A.; Dobens, Leonard L.; Tan, Nguan Soon; Mace, Peter D.; Link, Wolfgang; Kiss-Toth, Endre; et al. "Highlights of the 2nd international symposium on tribbles and diseases: tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer". (2019): http://hdl.handle.net/10400.1/12538.
  19. Henriques, V.; Martins, T.; Link, W.; Ferreira, B.I.. "The emerging therapeutic landscape of advanced melanoma". Current Pharmaceutical Design 24 5 (2018): 549-558. http://www.scopus.com/inward/record.url?eid=2-s2.0-85049050742&partnerID=MN8TOARS.
  20. Link, W.. "Knowledge-based drug discovery intensifies private appropriation of publicly financed research". The Lancet Oncology 19 8 (2018): 1017-1018. http://www.scopus.com/inward/record.url?eid=2-s2.0-85050801734&partnerID=MN8TOARS.
  21. Wolfgang Link; Pablo J. Fernandez-Marcos. "FOXO transcription factors at the interface of metabolism and cancer". International Journal of Cancer 141 12 (2017): 2379-2391. https://doi.org/10.1002/ijc.30840.
  22. Link W. "Immunology: Mind the immuno-connection gap.". (2017): http://europepmc.org/abstract/med/28437396.
  23. Hill R; Madureira PA; Ferreira B; Baptista I; Machado S; Colaço L; Dos Santos M; et al. "TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.". (2017): http://europepmc.org/abstract/med/28276427.
  24. Ferreira, B.I.; Lie, M.K.; Engelsen, A.S.T.; Machado, S.; Link, W.; Lorens, J.B.. "Adaptive mechanisms of resistance to anti-neoplastic agents". MedChemComm 8 1 (2017): 53-66. http://www.scopus.com/inward/record.url?eid=2-s2.0-85010716209&partnerID=MN8TOARS.
  25. Martins R; Lithgow GJ; Link W. "Long live FOXO: unraveling the role of FOXO proteins in aging and longevity.". (2016): http://europepmc.org/abstract/med/26643314.
  26. Cautain B; Castillo F; Musso L; Ferreira BI; de Pedro N; Rodriguez Quesada L; Machado S; et al. "Discovery of a Novel, Isothiazolonaphthoquinone-Based Small Molecule Activator of FOXO Nuclear-Cytoplasmic Shuttling.". (2016): http://europepmc.org/abstract/med/27936162.
  27. Tarrado-Castellarnau M; Cortés R; Zanuy M; Tarragó-Celada J; Polat IH; Hill R; Fan TW; Link W; Cascante M. "Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition.". (2015): http://europepmc.org/abstract/med/26375988.
  28. Hill R; Kalathur RK; Colaço L; Brandão R; Ugurel S; Futschik M; Link W; et al. "TRIB2 as a biomarker for diagnosis and progression of melanoma.". Biochemical Society Transactions 43 (2015): 1085-1088. http://europepmc.org/abstract/med/25586991.
  29. Wolfgang Link. "Molecular Inhibitors in Targeted Therapy". Molecular inhibitors in targeted therapy 1 1 (2015): https://doi.org/10.1515%2Fmotth-2015-0001.
  30. Cautain, B.; Hill, R.; De Pedro, N.; Link, W.. "Components and regulation of nuclear transport processes". FEBS Journal 282 3 (2015): 445-462. http://www.scopus.com/inward/record.url?eid=2-s2.0-84921797642&partnerID=MN8TOARS.
  31. Ferreira, B.I.; Hill, R.; Link, W.. "Caught in the crosshairs: Targeted drugs and personalized medicine". Cancer Journal (United States) 21 6 (2015): 441-447. http://www.scopus.com/inward/record.url?eid=2-s2.0-84948411505&partnerID=MN8TOARS.
  32. Ferreira BI; Hill R; Link W. "Special Review: Caught in the Crosshairs: Targeted Drugs and Personalized Medicine.". (2015): http://europepmc.org/abstract/med/26588674.
  33. Tarrado-Castellarnau, Miriam; Cortes, Roldan; Zanuy, Miriam; Tarrago-Celada, Josep; Polat, Ibrahim H.; Hill, Richard; Fan, Teresa W. M.; Link, Wolfgang; Cascante, Marta. "Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition". (2015): http://hdl.handle.net/10400.1/11207.
  34. Hill, Richard; Kalathur, Ravi Kiran Reddy; Callejas, Sergio; Colaço, Laura; Brandão, Ricardo; Serelde, Beatriz; Cebriá, Antonio; et al. "A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes". Breast Cancer Research 16 6 (2014): http://dx.doi.org/10.1186/s13058-014-0482-y.
  35. Hill, R.; Cautain, B.; De Pedro, N.; Link, W.. "Targeting nucleocytoplasmic transport in cancer therapy". Oncotarget 5 1 (2014): 11-28. http://www.scopus.com/inward/record.url?eid=2-s2.0-84893870810&partnerID=MN8TOARS.
  36. Mori, Mattia; Vignaroli, Giulia; Cau, Ylenia; Dinic, Jelena; Hill, Richard; Rossi, Matteo; Colecchia, David; et al. "Discovery of 14-3-3 Protein- Protein Interaction Inhibitors that Sensitize Multidrug- Resistant Cancer Cells to Doxorubicin and the Akt Inhibitor GSK690693". Chemmedchem 9 5 (2014): 973-983.
  37. Cortés, Roldán; Tarrado-Castellarnau, Míriam; Talancón, Daniel; López, Concepción; Link, Wolfgang; Ruiz, Daniel; Centelles, Josep Joan; Quirante, Josefina; Cascante, Marta. "A novel cyclometallated Pt(ii)–ferrocene complex induces nuclear FOXO3a localization and apoptosis and synergizes with cisplatin to inhibit lung cancer cell proliferation". Metallomics 6 3 (2014): 622. http://dx.doi.org/10.1039/c3mt00194f.
  38. Cautain, Bastien; de Pedro, Nuria; Murillo Garzón, Virginia; Muñoz de Escalona, María; González Menéndez, Victor; Tormo, José R.; Martin, Jesús; et al. "High-Content Screening of Natural Products Reveals Novel Nuclear Export Inhibitors". Journal of Biomolecular Screening 19 1 (2013): 57-65. http://dx.doi.org/10.1177/1087057113501389.
  39. Link Wolfgang; Madureira Patricia; Hill Richard. "Identifying new targets for personalized medicine". eLS. John Wiley & Sons, Ltd: Chichester (2013):
    DOI: 10.1002/9780470015902.a0024865
  40. Granda, T.G.; Cebrián, D.; Martínez, S.; Anguita, P.V.; López, E.C.; Link, W.; Merino, T.; et al. "Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases". Investigational New Drugs 31 1 (2013): 66-76. http://www.scopus.com/inward/record.url?eid=2-s2.0-84873832557&partnerID=MN8TOARS.
  41. Evensen, L.; Link, W.; Lorens, J.B.. "Image-based high-throughput screening for inhibitors of angiogenesis.". Methods in molecular biology (Clifton, N.J.) 931 (2013): 139-151. http://www.scopus.com/inward/record.url?eid=2-s2.0-84873518972&partnerID=MN8TOARS.
  42. Zanella, F.; dos Santos, N.R.; Link, W.. "Moving to the Core: Spatiotemporal analysis of forkhead Box O (FOXO) and nuclear factor-¿B (NF-¿B) nuclear translocation". Traffic 14 3 (2013): 247-258. http://www.scopus.com/inward/record.url?eid=2-s2.0-84873424232&partnerID=MN8TOARS.
  43. Wolfgang Link. "Nuclear accumulation of ß-catenin and forkhead box O3a in colon cancer: Dangerous liaison". World Journal of Biological Chemistry 3 9 (2012): 175-175. https://doi.org/10.4331%2Fwjbc.v3.i9.175.
  44. Kauselmann, G.; Dopazo, A.; Link, W.. "Identification of disease-relevant genes for molecularly-targeted drug discovery". Current Cancer Drug Targets 12 1 (2012): 1-13. http://www.scopus.com/inward/record.url?eid=2-s2.0-84855851646&partnerID=MN8TOARS.
  45. Martínez González, S.; Hernández, A.I.; Varela, C.; Rodríguez-Arístegui, S.; Lorenzo, M.; Rodríguez, A.; Rivero, V.; et al. "Identification of ETP-46321, a potent and orally bioavailable PI3K a, d inhibitor". Bioorganic and Medicinal Chemistry Letters 22 10 (2012): 3460-3466. http://www.scopus.com/inward/record.url?eid=2-s2.0-84860467003&partnerID=MN8TOARS.
  46. Martinez Gonzalez, Sonia; Isabel Hernandez, Ana; Varela, Carmen; Rodriguez-Aristegui, Sonsoles; Maria Alvarez, Rosa; Belen Garcia, Ana; Lorenzo, Milagros; et al. "Imidazo 1,2-a pyrazines as novel PI3K inhibitors". Bioorganic & Medicinal Chemistry Letters 22 5 (2012): 1874-1878.
  47. Martinez Gonzalez, Sonia; Isabel Hernandez, Ana; Varela, Carmen; Lorenzo, Milagros; Ramos-Lima, Francisco; Cendon, Elena; Cebrian, David; et al. "Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR". Bioorganic & Medicinal Chemistry Letters 22 16 (2012): 5208-5214.
  48. Link, W.. "Editorial". Current Drug Targets 12 9 (2011): 1232-1234. http://www.scopus.com/inward/record.url?eid=2-s2.0-79960000513&partnerID=MN8TOARS.
  49. Link, Wolfgang. "Context-dependent therapeutic potential of FOXO proteins in oral squamous cell carcinoma". Oral Oncology 47 4 (2011): 229-230.
  50. Hung, Mien-Chie; Link, Wolfgang. "Protein localization in disease and therapy". Journal of Cell Science 124 20 (2011): 3381-3392.
  51. Zanella, F.; Link, W.; Carnero, A.. "Understanding FOXO, new views on old transcription factors". Current Cancer Drug Targets 10 2 (2010): 135-146. http://www.scopus.com/inward/record.url?eid=2-s2.0-77950680198&partnerID=MN8TOARS.
  52. Evensen, Lasse; Micklem, David R.; Link, Wolfgang; Lorens, James B.. "A Novel Imaging-based High-throughput Screening Approach to Anti-angiogenic Drug Discovery". Cytometry Part a 77A 1 (2010): 41-51.
  53. Pastor, J.; Martinez, S.; Alvarez, R. M.; Varela, C.; Hernandez, A. I.; Rodriguez, S.; Oyarzabal, J.; et al. "Amino-alkyl substituted fused imidazoles: potent, selective and orally bioavailable inhibitors of PI3K". Ejc Supplements 8 7 (2010): 62-62.
  54. Zanella, F.; Renner, O.; Garcia, B.; Callejas, S.; Dopazo, A.; Peregrina, S.; Carnero, A.; Link, W.. "Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells". Oncogene 29 20 (2010): 2973-2982.
  55. Evensen, Lasse; Link, Wolfgang; Lorens, James B.. "Imaged-based High-Throughput Screening for Anti-Angiogenic Drug Discovery". Current Pharmaceutical Design 16 35 (2010): 3958-3963.
  56. Rabal, Obdulia; Link, Wolfgang; Serelde, Beatriz G.; Bischoff, James R.; Oyarzabal, Julen. "An integrated one-step system to extract, analyze and annotate all relevant information from image-based cell screening of chemical libraries". Molecular Biosystems 6 4 (2010): 711-720.
  57. Zanella, Fabian; Lorens, James B.; Link, Wolfgang. "High content screening: seeing is believing". Trends in Biotechnology 28 5 (2010): 237-245.
  58. Link, W.. "Exploring the biological space of FOXO regulation: discovery of therapeutic targets and small molecule inhibitors for anticancer therapy". New Biotechnology 25 (2009): S3-S3.
  59. Zanella, Fabian; Rosado, Aranzazu; Garcia, Beatriz; Carnero, Amancio; Link, Wolfgang. "Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators". Bmc Cell Biology 10 (2009):
  60. Link, Wolfgang; Oyarzabal, Julen; Serelde, Beatriz G.; Isabel Albarran, Maria; Rabal, Obdulia; Cebria, Antonio; Alfonso, Patricia; et al. "Chemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-Kinases". Journal of Biological Chemistry 284 41 (2009): 28392-28400.
  61. Carnero, Amancio; Blanco-Aparicio, Carmen; Renner, Oliver; Link, Wolfgang; Leal, Juan F. M.. "The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications". Current Cancer Drug Targets 8 3 (2008): 187-198.
  62. Rosado, Aranzazu; Zanella, Fabian; Garcia, Beatriz; Carnero, Amancio; Link, Wolfgang. "A Dual-Color Fluorescence-Based Platform to Identify Selective Inhibitors of Akt Signaling". Plos One 3 3 (2008):
  63. Zanella, Fabian; Rosado, Aranzazu; Garcia, Beatriz; Carnero, Amancio; Link, Wolfgang. "Chemical Genetic Analysis of FOXO Nuclear-Cytoplasmic Shuttling by Using Image-Based Cell Screening". Chembiochem 9 14 (2008): 2229-2237.
  64. Guijarro, Maria V.; Link, Wolfgang; Rosado, Aranzazu; Leal, Juan F. M.; Carnero, Amancio. "MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation". Carcinogenesis 28 12 (2007): 2443-2450.
  65. Liebel, Urban; Link, Wolfgang. "Meeting report: trends and challenges in high content analysis.". Biotechnology journal 2 8 (2007): 938-40.
  66. Zanella, Fabian; Rosado, Aranzazu; Blanco, Fernando; Henderson, Beric R.; Carnero, Amancio; Link, Wolfgang. "An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays". Assay and Drug Development Technologies 5 3 (2007): 333-341.
  67. Link, W; Rosado, A; Fominaya, J; Thomas, JE; Carnero, A. "Membrane localization of all class IPI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt". Journal of Cellular Biochemistry 95 5 (2005): 979-989.
  68. Link, WA; Ledo, F; Torres, B; Palczewska, M; Madsen, TM; Savignac, M; Albar, JP; Mellstrom, B; Naranjo, JR. "Day-night changes in downstream regulatory element antagonist modulator/potassium channel interacting protein activity contribute to circadian gene expression in pineal gland". Journal of Neuroscience 24 23 (2004): 5346-5355.
  69. Mellstrom, Britt; Torres, Begona; Link, Wolfgang A; Naranjo, Jose R. "The BDNF gene: exemplifying complexity in Ca2+ -dependent gene expression.". Critical reviews in neurobiology 16 1-2 (2004): 43-9.
  70. Moneo, V; Guijarro, MD; Link, W; Carnero, A. "Overexpression of cyclin D1 inhibits TNF-induced growth arrest". Journal of Cellular Biochemistry 89 3 (2003): 484-499.
  71. Carnero, A.; Blanco, C.; Blanco, F.; Castro, M.E.; Guijarro, M.V.; Fominaya, J.; Link, W.; et al. "Exploring cellular senescence as a tumor suppressor mechanism". Clinical and Translational Oncology 5 5 (2003): 249-265. http://www.scopus.com/inward/record.url?eid=2-s2.0-33646253025&partnerID=MN8TOARS.
  72. Sanz, C; Mellstrom, B; Link, WA; Naranjo, JR; Fernandez-Luna, JL. "Interleukin 3-dependent activation of DREAM is involved in transcriptional silencing of the apoptotic hrk gene in hematopoietic progenitor cells". Embo Journal 20 9 (2001): 2286-2292.
  73. Ledo, F; Carrion, AM; Link, WA; Mellstrom, B; Naranjo, JR. "DREAM-alpha CREM interaction via leucine-charged domains derepresses downstream regulatory element-dependent transcription". Molecular and Cellular Biology 20 24 (2000): 9120-9126.
  74. Link, WA; Kauselmann, G; Mellstrom, B; Kuhl, D; Naranjo, JR. "Induction of glycerol phosphate dehydrogenase gene expression during seizure and analgesia". Journal of Neurochemistry 75 4 (2000): 1419-1428.
  75. Ledo, F; Link, WA; Carrion, AM; Echeverria, V; Mellstrom, B; Naranjo, JR. "The DREAM-DRE interaction: key nucleotides and dominant negative mutants". Biochimica Et Biophysica Acta-Molecular Cell Research 1498 2-3 (2000): 162-168.
  76. Carrión, A.M.; Link, W.A.; Ledo, F.; Mellström, B.; Naranjo, J.R.. "DREAM is a Ca2+-regulated transcriptional repressor". Nature 398 6722 (1999): 80-84. http://www.scopus.com/inward/record.url?eid=2-s2.0-0033521983&partnerID=MN8TOARS.
  77. Carrion, A.M.; Taylor, J.S.; Link, W.; Morcuende, S.; Mellsrtrom, B.; Naranjo, J.R.. "Early gene induction and spinal cord function". DOLOR 11 1 (1996): 22-24. http://www.scopus.com/inward/record.url?eid=2-s2.0-0029960761&partnerID=MN8TOARS.
  78. LINK, W; KONIETZKO, U; KAUSELMANN, G; KRUG, M; SCHWANKE, B; FREY, U; KUHL, D. "SOMATODENDRITIC EXPRESSION OF AN IMMEDIATE-EARLY GENE IS REGULATED BY SYNAPTIC ACTIVITY". Proceedings of the National Academy of Sciences of the United States of America 92 12 (1995): 5734-5738.
Online resource
  1. Link, Wolfgang. Components and regulation of nuclear transport processes. 2015. http://www.yada-yada.co.uk/Blackwell/PAI/Audio/Wolfgang_Jan2015.mp3.
Thesis / Dissertation
  1. Raposo, Catarina Martins. "Study of the TRIB2 protein network". Master, 2019. http://hdl.handle.net/10400.1/13375.
  2. Henriques, Vanessa Mendes. "Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK". Master, 2017. http://hdl.handle.net/10400.1/10705.
  3. Santos, Marta Machado Pereira dos. "Characterization of TRIB2-mediated resistance to anti-cancer drugs". Master, 2016. http://hdl.handle.net/10400.1/8442.
  4. Silva, Neuton Pedro Gorjão da. "TRIB2 confers resistance to MAPK and TOR1 inhibitors". Master, 2016. http://hdl.handle.net/10400.1/9833.
  5. Baptista, Inês do Carmo Viegas. "Characterization of TRIB2 following PI3K inhibition". Master, 2015. http://hdl.handle.net/10400.1/7684.
  6. Colaço, Laura Guerreiro. "Investigating the role and function of Tribbles 2 (TRIB2) in drug resistance within cancer". Master, 2014. http://hdl.handle.net/10400.1/8366.

Intellectual property

  1. Link, Wolfgang; Pastor J. F.. 2012. "New amino-imidazolothiadiazole compound useful for treating e.g. cancer, cardiovascular disease, viral infection, inflammation, neurological disorder, bone disorder, atherosclerosis, pulmonary fibrosisrestenosis, stroke, diabetes".
  2. Link, Wolfgang. 2003. "Caenorhabditis parkin gene and transgenic nematodes for use as Parkinson's disease models and for drug screening".
  3. Link, Wolfgang. 2000. "Calcium-dependent transcriptional regulator DREAM and its cDNA and methods for drug screening".


Other output
  1. Anti-cancer Drugs: Discovery, Development and Therapy. 2015. Wolfgang Link. https://doi.org/10.1007%2F978-3-319-21683-6_6.
  2. Finding novel targets for anticancer therapy. 2010. Link, W.. http://www.scopus.com/inward/record.url?eid=2-s2.0-77953451665&partnerID=MN8TOARS.
Spin-off company
  1. 2020. Refoxy Pharmaceuticals GMBH, Berlin/Boston. Drug Discovery. https://www.refoxy.com/.
  2. 2010. exCELLerate S.L.. Image-based Drug Discovery.

Oral presentation

Presentation title Event name
Host (Event location)
2022/09/29 High content imaging-based discovery of novel targets and small molecule compounds for healthy aging and anticancer therapy. (Invited talk). Jornada de usuarios de High Content Screening, 29th September 2022 at Instituto de Salud Carlos III, Centro Nacional de Microbiología, Majadahonda, Spain
2022/06/27 Understanding and Targeting the TRIB2-AKT-FOXO axis in human cancer and aging. III International Meeting of the Portuguese Society of Genetics, 27th and 28th June 2022 at the University of Évora, Portugal
2021/09/06 Emerging targets and small molecule drug candi-dates to overcome cancer therapy resistance, Invited talk, STRATAGEM, Annual conference 6th September 2021, Prague, Czech Republic STRATAGEM, Annual conference
STRATAGEM (Prague, Czech Republic)
2021/01/07 HTVS protocol to identify non-covalent inhibitors of CRM1, João Gonçalo Nunes Sequeira *, Wolfgang Link, Miguel Machuqueiro, MOL2NET'21, Conference on Molecular, Biomedical & Computational Sciences and Engineering, 7th ed., Chem-Bioinformatics Congress München, Germany-Chapell Hill, USA, 2021
2020/04/22 Tribbles pseudokinases in anti-cancer therapy resistance International Web Symposium, Pseudokinases and Tribbles - from Molecules to Therapy
Helmholtz Zentrum München, Germany (Madrid, Spain)
2020/02/28 Targeting FOXO proteins to extend lifespan and fight cancer and anti-cancer drug resistance Invited talk, STRATAGEM, Annual conference 28th February 2020, Belgrade, Serbia STRATAGEM, Annual conference
COST (Belgrade, Serbia)
2020/01/31 Spinning off academic discovery of FOXO - modulating compounds into small biotech companies TRANSAUTOPHAGY Translational Workshop
COST (Faro, Portugal)
2020/01/15 Harmine and Piperlongumine revert TRIB2-mediated drug resistance. Invited talk International Online Symposium on Synthesis and nanodelivery strategies for new therapeutic tools against Multidrug Resistant Tumours
COST STRATAGEM (Madrid, Spain)
2019/09/20 Targeting the TRIB2 - FOXO axis of anti-cancer drug resistance; September 20, Invited Talk at General, Hospital of Vienna, Austria. Stratagem WG meeting
General Hospital of Vienna (Vienna, Austria)
2019/06/07 Targeting FOXO proteins to fight cancer and extend lifespan; IIBM seminar, June 7, Madrid, Spain Seminar Cycle
IIBM (Madrid, Spain)
2019/04/12 Tribbles proteins determine the level of activity of the oncokinase AKT Jornadas Liga Portuguese Contra o Cancro
Liga Portuguese Contra o Cancro, IPOLFG (Lisbon, Portugal)
2019/03/26 High content screening-based discovery of natural products from microalgae to treat cancer and slow aging, I Seminário Projeto ALGARED+, March 26, Faro, Portugal Seminário Projeto ALGARED+
CCMAR (Faro, Portugal)
2018/12/13 Targeting FOXO proteins to fight cancer and extend lifespan. “Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery” Conference, December 13, 2018, La Laguna, Tenerife, Spain Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery” Conference
COST (tenerife, Spain)
2018/10/16 TRIB2-mediated activation of AKT confers resistance to anti-cancer therapy, International workshop on The cell biology behind the ONCOGENIC PIP3 LIPIDS October 16, 2018, Baeza, Spain International workshop on “The cell biology behind the ONCOGENIC PIP3 LIPIDS
Universidad Internacional de Andalucía - Sede Antonio Machado de Baeza (Baeza, Spain)
2018/05/29 Targeted strategies for the discovery of chemical compounds with therapeutic potential against cancer, Universidad de La Laguna, Instituto de Productos Naturales y Agrobiología del CSIC, May 29,2018, Tenerife, Spain Seminar
Universidad de La Laguna, Instituto de Productos Naturales y Agrobiología del CSIC (La laguna, Spain)
2018/05/08 TRIB2 acts as a major driver of tumorigenesis and anti-cancer drug resistance 2th International Symposium on “TRIBBLES and Diseases"
TRIBBLES Network (Beijing, China)
2018/04/18 Characterizing the clinical relevance and the mechanism underlying TRIB2-mediated drug resistance to MEK inhibitors in the context of melanoma III Jornadas Liga Portuguese Contra o Cancro
Liga Portuguese Contra o Cancro (Lisbon, Portugal)
2018/03/03 Targeted drug discovery for Precision Oncology 5th MC/WG Meeting
COST Action CM1407 (Salini Resort, Malta)
2017/06/06 Characterization of TRIB2 mediated resistance to anti-melanoma drugs II Jornadas de Investigação em Oncologia em Portugal
IPOLFG (Lisbon, Portugal)
2017/05/19 Means to restore tumor suppressor genes in pancreatic cancer 2nd Porto Precision OONCOLOGY Meeting
IPATIMUP (Porto, Portugal)
2017/05/08 TRIB2, FOXO and p53: The evil axis of anti-cancer drug resistance 8th Meeting on Signal Transduction
SINAL (Lisbon, Portugal)
2017/03/03 FOXO Caught in the Crosshairs: Discovering Targets and Drugs for Innovative Anti-Cancer Therapies COST Annual Meeting
Jagiellonian University (Krakow, Poland)
2016/10/06 TRIB2, FOXO and p53: The evil axis of anti-cancer drug resistance Invited seminar
University of Sheffield, Medical School, Sheffield (Sheffield, United Kingdom)
2016/06/18 FOXO Caught in the Crosshairs: Strategies of Innovative Drug Discovery Invited Seminar
CCMAR (faro, Portugal)
2016/06/08 TRIB2 as an oncogenic FOXO suppressor protein Tribbles Proteins at the Interface of Metabolism and Cancer
TRIBBLES network (Faro, Portugal)
2016/04/04 Discovering ways to tackle cancer drug resistance Invited seminar
IIBM-CSIC (Madrid, Spain)
2016/02/12 TIBBLES breaking bad: TRIB2 confers resistance to anti-cancer drugs Invited seminar
IdiPAZ Madrid (Madrid, Spain)
2015/04/23 TRIB2 acts as an oncogene in melanoma and confers drug resistance by deregulating the AKT signalling network Biochemical Society Conference, Tribbles at the crossroads of metabolism, cancer, immunity and development
Biochemical Society (Budapest, Hungary)
2014/10/14 Translocation in Cancer Therapy CIBICAN Conference on Molecular Pharmacology and Mechanisms of New Anticancer Drugs
CIBICAN (Tenerife, Spain)
2013/07/05 Targeting the subcellular localization of tumor suppressors and oncogenic proteins as anti-cancer therapy Invited seminar
Fundación Medina, University of Granada (Granada, Spain)
2013/06/21 FoxO Proteins as Potential Targets for Anti-Cancer Therapy FOXO3 and Related Transcription Factors in Development, Aging and Exceptional Longevity
Longevity Consortium, US (San Francisco, United States)
2012/07/04 Exploring the spatio-temporal regulation of disease-relevant proteins for the development of anti-cancer therapies Invited Seminar
Universita degli Studi di Milano (Milan, Italy)
2012/04/14 Exploring the spatio-temporal regulation of disease-relevant proteins for the development of anti-cancer therapies SINAL2012, 6th National Meeting on Cell Signaling, University of Minho
SINAL (Braga, Portugal)
2012/03/16 Protein localization in disease and therapy 3rd Scientific Meeting of Institute for Biotechnology and Bioengineering Instituto Superior Técnico
Instituto Superior Técnico (Lisbon, Portugal)
2011/07/07 Protein localization in disease and therapy Invited seminar
nstitute for Biotechnology Bioengineering Dep. Ciências Biomédicas e Medicina, Universidade do Algarve (Faro, Portugal)
2011/06/14 Exploring the spatio-temporal regulation of disease-relevant proteins for the development of therapeutic strategies Invited seminar
Institut de Recerca, Hospital Universitari Vall d'Hebron
2011/05/24 Pathway-oriented target and drug discovery for anticancer therapy Invited seminar
UKE Eppendorf, University Hamburg (Hamburg, Germany)
2011/05/17 Mislocalization and therapeutic restoration of normal protein localization in human diseases BD Biosciences Meeting
University Heidelberg (Heidelberg, Germany)
2010/06/24 High content imaging-based discovery of novel targets and small molecule inhibitors for anticancer therapy 2nd Annual Cellular Imaging Analysis,
Trinity College (Dublin, Ireland)
2010/02/11 Image based pathway analysis of FOXO regulation leads to the discovery of therapeutic targets and small molecule inhibitors for anticancer therapy 22nd Lorne Cancer Conference
Lorne Cancer (Lorne, Australia)
2009/10/21 A hierarchical network of image based screens and counter screens to explore strategies for restoring FOXO activity in human cancer 5th annual Global Imaging Summit
Global Imaging (Berlin, Germany)
2009/06/22 Exploring the Biological Space of FOXO Transcription Factors: Discovery of Kinase Inhibitors for Anticancer Therapy BIT's Annual World Cancer Congress
BTI (Beijing, China)
2008/09/10 Large-scale cell biology – Tackling the complexity of biological systems Invited Seminar
Centro Nacional de Investigaciones Cardiovasculares (CNIC) (Madrid, Spain)
2008/08/02 Using High Content Cellular Imaging to crack the FOXO Code 4th annual Global Imaging Summit
GIS (cologne, Germany)
2008/07/09 Hunting with the Fox – Loss of Function screen identifies suppressors of FoxO function Informa´s MicroRNA & RNAi Industry Summit
Informa (London, United Kingdom)
2008/06/12 Screening for Content - Image-based Anticancer Drug Discovery BIT's Annual World Cancer Congress
BIT (Shanghai, China)
2008/03/11 Cellular pathway analysis using High-Content Imaging Informa´s 2nd annual High Content Analysis
Informa (berlin, Germany)
2008/03/06 High-Content Screening of complex RNAi and Compound libraries Invited seminar
University of Bergen (Bergen, Norway)
2008/02/05 Screening for Content - Image-based Anticancer Drug Discovery Personalised Medicine Partnerships in Oncology & Cardiology
Next Level Pharma (Munich, Germany)
2008/01/09 Chemical genetic approach to study the regulation of nuclear-cytoplasmic shuttling of FoxO using High-Content Imaging CHI´s Fifth Annual High Content Analysis
CHI (San Francisco, United States)
2007/06/29 Applying the Power of High Content Screening to Anti-Cancer Drug Discovery Invited Seminar
Centro de Investigación Príncipe Felipe (CIPF)
2007/06/27 High Content Screening-based Drug Discovery Informa´s High Content Analysis
Informa (Vienna, Austria)
2007/06/08 An image-based approach to screen for inhibitors of the PI3K/Akt signaling pathway X Congreso de la Sociedad Ibérica de Citometría (SIC)
Sociedad Ibérica de Citometría (valencia, Spain)
2006/09/29 Pathway specific anti-cancer drug discovery: Identification of therapeutic targets associated with PI3K/Akt signalling. Screening Europe
SEN (Prague, Czech Republic)
2006/09/26 Applying the Power of High Content Screening to Anti-Cancer Drug Discovery Invited Seminar
Institute for Research in Biomedicine (IRB) (Barcelona, Spain)
2004/09/22 Development of cell - based high throughput assays targeting the PI3´K/Akt pathway for anti-cancer drug discovery III jornadas oncológicas CIC Apoptosis y Cáncer
CIC (Salamanca, Spain)
2003/09/06 Day-Night changes in DREAM activity contribute to circadian gene expression in pineal gland X Congreso de la Sociedad Española de Neurosciencias
Sociedad Española de Neurosciencias (Lerida, Spain)


Thesis Title
Degree Subject (Type)
Institution / Organization
2017/04/01 - Current Characterizing the role of FOXO regulators and FOXO isoforms in cancer
Universidade do Algarve, Portugal
2020/04/01 - 2021/03/31 Generation of drug resistant cell lines as a model to study melanoma, pancreatic cancer and glioblastoma.
Supervisor of Inês Grenho
Universidade do Algarve, Portugal
2019/09/01 - 2021/01/29 Descoberta de moduladores de FOXO para tratamentos anticancerígenos e antienvelhecimento
Universidade do Algarve, Portugal
Universidade do Algarve, Portugal
2017/09/01 - 2018/06/30 Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK
Universidade do Algarve - Campus de Gambelas, Portugal
2016/09/01 - 2017/10/15 Study of the TRIB2 protein network
2014/09/01 - 2015/07/04 Characterization of TRIB2 following PI3K inhibition
Universidade do Algarve - Campus de Gambelas, Portugal
2014/09/01 - 2015/06/30 Characterization of TRIB2-mediated resistance to anti-cancer drugs
Universidade do Algarve - Campus de Gambelas, Portugal
2014/09/01 - 2015/06/30 TRIB2 confers resistance to MAPK and mTOR1 inhibitors
Universidade do Algarve - Campus de Gambelas, Portugal
2013/09/01 - 2014/06/30 Investigating the role and function of Tribbles 2 (TRIB2) in drug resistance within cancer
Universidade do Algarve - Campus de Gambelas, Portugal
2005/12/01 - 2009/05/08 Development of Technological Platforms for the identification of Novel Cellular Modulators of FOXO activity
Supervisor of Fábian Zanella de Sá
Centro Nacional de Investigaciones Oncológicas, Spain

Event organisation

Event name
Type of event (Role)
Institution / Organization
2022/06/29 - Current Webinar with Robert A. Weinberg (USA) Whitehead Institute for Biomedical Research with over 300 participants 29 June 2022 (2022/06/06)
2022/12/16 - 2022/12/16 Online Panel Discussion with Vera Gorbunova (USA) and Joris Deelen (Germany), Decoding the genetic secrets of extreme longevity. December 16th, 2022 (2022/12/16)
2020/01/30 - 2020/01/31 2nd Joint WG4-WG5 TRANSAUTOPHAGY, Faro/Portugal (2020/01/30 - 2020/01/31)
Congress (Co-organisor)
2016/06/08 - 2016/06/09 International Meeting: ¿Tribbles Proteins at the Interface of Metabolism and Cancer (2016/06/08 - 2016/06/09)
Congress (President of the Organising Committee)
Universidade do Algarve - Campus de Gambelas, Portugal
2010/10/04 - 2010/10/05 BD Pathway Users Workshop (2010/10/04 - 2010/10/05)
Workshop (President of the Organising Committee)
2007/03/26 - 2007/03/27 High Content Analysis, Spain, 2007 (2007/03/26 - 2007/03/27)
Congress (President of the Organising Committee)
Centro Nacional de Investigaciones Oncológicas, Spain

Conference scientific committee

Conference name Conference host
2018/09/21 - 2018/09/22 SINAL, 9th Meeting on Signal Transduction SINAL


Activity description Institution / Organization
2019/10/01 - Current Expert advisor for European FET Expert, Trendington; Prefet. Defining topics for European FET call
2001/03/01 - Current Expert advisor for pharmaceutical industry Supervisor, Analysis of PI3K mutants for Eli Lilly, Indianapolis, EE UU Advisor, Consulting for Consorcio NanoFarma de vehiculización de fármacos (Drug delivery), project CENIT, Spain Advisor, Consulting for Bayer Pharma AG targeting Drug Resistance in Cancer Advisor, Apollo Ventures, funding anti-aging companies

Course / Discipline taught

Academic session Degree Subject (Type) Institution / Organization
2006/10/01 - Current Lecturer, PhD Course, University of Valencia (UV) Co-cordinator, Course on high content imaging, CNIO/Madrid Lecturer, Master Biotechnology, University of Barcelona (UB) Lecturer, ANGIOKEM, Rhodes, Greece Lecturer, Master Biotechnology, (UB) Lecturer, Master Biomedicine, UAlg Professor, Problem-based learning Medicine, UAlg Lecturer, Undergraduate Courses in Human genetics, UAlg Co-coordinator, Master Course Oncobiology, UAlg Lecturer, Signal Transduction, Cancer Therapy, Master Course, UAlg Lecturer, ESCCA Summer School (UV)

Evaluation committee

Activity description
Institution / Organization Funding entity
2019/10/01 - Current TubInTrain Member of the international Evaluation Board of TubInTrain, European Joint Doctorate on chemistry and biology and focused on the microtubules breakdown (www.tubintrain.eu).

Other jury / evaluation

Activity description Institution / Organization
2012/03/11 - Current EVALUATION FOR RESEARCH FUNDING ORGANISATIONS Austrian Science Fund (ASF, Austria) Dutch Cancer Society (Netherlands) European Research Council (European Union) FCT and Fundo iMM Laço (Portugal) Health Research Council New Zealand Italian Ministry of Health and Agenzia Italina del Farmaco (Italy) North West Cancer Research, Leuka and the Brain Tumour Charity (UK) Spanish Agency of Evaluation and Assessment (Spain) University of Cape Town (South Africa) University of Macau (China)
2012/03/01 - Current PARTICIPATION IN INTERNATIONAL NETWORKS COST Action: CM1106, Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells COST Action: BM1204, An integrated European platform for pancreas cancer research: from basic science to clinical and public health interventions for a rare disease COST Action: CM1407, Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery Longevity Consortium, US (www.longevityconsortium.org)
2009/01/01 - Current JOURNAL REVIEWER FOR (selected list) Biochemical J., Cancers, Carcinogenesis, ChemBioChem, Chemical Reviews, Current Medicinal Chemistry, Current Molecular Medicine, Drug Discovery Today, European Journal of Pharmacology, FEBS Letters, Frontiers in Immunology, Hepatology, J Cell Biochem, J Cell Science, J Cellular and Molecular Medicine, Medical Research Reviews, Nature Chemical Biology, Nature Comm., Neoplasia, Oncogene, Oncology Letters, Oral OncologyPloS ONE, PNAS, Redox Biology, Scientific Reports, Theranostics, Trends Cell Biology
2010/01/01 - 2020/12/31 JOURNAL REVIEWER FOR: Oxidative Medicine and Cellular Longevity, PloS ONE, PNAS, Redox Biology, Rejuvenation Research, Scientific Reports, SpringerPlus, Targeted Oncology, Trends Cell Biology, WJBC, World Journal of Medicine and Medical Science Research
2010/01/01 - 2020/03/31 JOURNAL REVIEWER FOR: Analytical Chemistry, Apoptosis, BBA - Molecular Basis of Disease, Biochemical J., Biotechniques, Biotechnology J, BMC Cell Biology, Cancer Drug Resistance, Carcinogenesis, ChemBioChem, Chemical Research in Toxicology, Chemical Reviews, Cellular Signalling, Current Medicinal Chemistry, Current Molecular Medicine, Cytometry A, Drug Discovery Today, EBioMedicine, European Journal of Pharmacology, Expert Opinion On Drug Discovery, F1000_Faculty Reviews, FEBS Letters, Gene, Gynecologic Oncology, Hepatology
2010/01/01 - 2020/03/31 JOURNAL REVIEWER FOR: International Journal of Cancer, Internat J Developmental Neurosci, International Journal of Oncology, J Biomol Screening, J Cell Biochem, J Cell Science, J Gastrointestinal and Liver Diseases, J Hematology & Oncology, J Inorg Biochem, Journal of Visualized Experiments, Life Sciences, Medical Research Reviews, Micromachines, Molecular Biology Reports, Molecular Imaging, Molecules, Nature Chemical Biology, Nature Comm., Neoplasia, Neuroscience Letters, Oncogene, Oncology Letters, Oncology Reports, Oncotarget, Oral Oncology


2000 PhD
Universität Hamburg, Germany